| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A recombinant partial protein (within amino acids 702-848) from the human protein was used as the immunogen for the c-RET antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
c-RET Antibody is an antibody targeting c-RET. Host: Mouse. Monoclonal. Clone: RET/8787. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: c-RET.
- Immunogen: A recombinant partial protein (within amino acids 702-848) from the human protein was used as the immunogen for the c-R….
- Species reactivity: Human.
- Localization: Cytoplasmic, nuclear, cell surface.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
